18:45 , Oct 20, 2017 |  BioCentury  |  Finance

Fast inflections

Longitude Capital joined Cydan Development Inc. ’s syndicate with the expectation that spinouts from the rare disease accelerator can deliver returns within three to five years. The company sources rare disease assets from academia, not-for-profits...
00:34 , Oct 20, 2017 |  BC Week In Review  |  Financial News

Orphan drug accelerator Cydan raises $34M

Cydan Development Inc. (Cambridge, Mass.), which operates an accelerator that spins out rare genetic disease companies, raised $34 million on Oct. 17 in a round led by existing investor New Enterprise Associates (NEA). New investor...
22:58 , Oct 17, 2017 |  BC Extra  |  Financial News

Orphan drug accelerator Cydan raises $34M

Cydan Development Inc. (Cambridge, Mass.), which operates an accelerator that spins out rare genetic disease companies, raised $34 million in a round led by existing investor New Enterprise Associates (NEA). New investor Longitude Capital and...
18:34 , Jun 9, 2017 |  BioCentury  |  Regulation

New SOC in sickle cell?

If FDA follows ODAC’s recommendation to approve Endari L-glutamine from Emmaus Life Sciences Inc. , the candidate is likely to become the backbone of sickle cell therapy. On May 24, FDA’s Oncologic Drugs Advisory Committee...
17:34 , May 26, 2017 |  BC Week In Review  |  Clinical News

FDA grants IMR-687 rare pediatric disease designation

Imara Inc. (Cambridge, Mass.) said FDA granted rare pediatric disease designation to IMR-687 to treat sickle cell disease (SCD). Imara said it is the first SCD candidate to receive the designation from the agency. The...
23:48 , Feb 28, 2017 |  BC Innovations  |  Distillery Techniques

Assays and screens

TECHNOLOGY: Cell-free assays A synaptosome-based assay of long-term synaptic potentiation could be used to screen therapies to treat AD. The assay involved isolating synaptosomes from frozen, postmortem parietal cortex samples from AD patients and unaffected...
19:59 , Dec 6, 2016 |  BC Week In Review  |  Clinical News

IMR-687: Ph I started

Imara began a double-blind, placebo-controlled, U.S. Phase I trial to evaluate oral IMR-687 in about 42 healthy volunteers. Imara has exclusive, worldwide rights to IMR-687 from H. Lundbeck (see BioCentury, April 18 ). Imara Inc....
07:00 , Aug 4, 2016 |  BC Innovations  |  Finance

2Q16 Public-Private Partnership Roundup

A new consortia revival helped boost public-private partnerships (PPPs) in 2Q16 to the highest total in two years. Newly announced preclinically focused deals jumped 30% over the relatively sluggish first quarter, from 56 PPPs to...
07:00 , May 30, 2016 |  BioCentury  |  Emerging Company Profile

Straightening out sickle cell

Imara Inc .'s phosphodiesterase-9 inhibitor, IMR-687 , is a potentially disease-modifying candidate for sickle cell disease that could avoid the toxicities and dosing challenges associated with more advanced products. Sickle cell disease is a genetic...
07:00 , Apr 18, 2016 |  BioCentury  |  Finance

Sickle syndicate

Orphan drug accelerator Cydan Development Inc. gathered enough preclinical data to convince its investor syndicate that sickle cell candidate IMR-687 is an asset worth building a company around. Cydan debuted in 2013 to identify, de-risk...